These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34184542)

  • 1. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
    Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
    Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
    Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
    Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
    Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
    Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
    Cheng Q; Tang Y; Liu F; Li X; Fang D
    Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.
    Poto R; Cristinziano L; Criscuolo G; Strisciuglio C; Palestra F; Lagnese G; Di Salvatore A; Marone G; Spadaro G; Loffredo S; Varricchi G
    Front Immunol; 2024; 15():1443704. PubMed ID: 39188724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
    Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
    Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
    Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
    Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib for the treatment of graft-versus-host disease.
    Ali H; Salhotra A; Modi B; Nakamura R
    Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of vincristine sensitivity in retinoblastoma through Janus kinase inhibition by ruxolitinib.
    Ke F; Wang N; Zhang X; Liu R; Ren T; Ke J; Yang J; Yan H; Ma J
    Anticancer Drugs; 2024 Aug; 35(7):615-622. PubMed ID: 38742728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
    Dai Z; Chen J; Chang Y; Christiano AM
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
    Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.
    Fante MA; Holler E; Schmidt B; Wolff D; Ehrl Y; Plentz A
    Bone Marrow Transplant; 2019 May; 54(5):762-764. PubMed ID: 30349038
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
    González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
    Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.